National Science Day 2026 & Biotech Infrastructure Leap

**Overview** On National Science Day, March 1, 2026, Union Minister Dr. Jitendra Singh inaugurated the state-of-the-art "Central Facility for Recombinant Cells and Sensors" at the BRIC-Rajiv Gandhi Centre for Biotechnology (BRIC-RGCB) in Thiruvananthapuram, advancing India’s biomanufacturing vision alongside prominent scientific outreach initiatives. **Key Highlights** • The advanced research facility was developed by the Department of Biotechnology (DBT) with an investment of approximately ₹60 crore. • A new dedicated Good Manufacturing Practice (GMP) facility was also announced with an ₹80 crore investment in two phases. • Over the past decade, India's bioeconomy has remarkably expanded 16-fold, growing from $10 billion to nearly $166 billion. • The number of biotechnology startups in the country has surged from around 50 in 2014 to over 11,000 today. • The new facility actively houses a large panel of engineered recombinant cells and advanced screening systems for drug discovery. • Research focuses heavily on combating non-communicable diseases, particularly colon, oral, breast, and cervical cancers. • The launch perfectly aligns with the recently introduced BioE3 Policy (Economy, Environment, and Employment). • Concurrent National Science Day celebrations involved CSIR outreach to powerfully promote grassroots biodiversity and scientific awareness. **Key Developments / Drivers** This infrastructure development represents a critical milestone in India's rapid transition toward a bio-driven economy. The facility immediately addresses the pressing need for rapid target-specific drug discovery and advanced medical genomics. Furthermore, the GMP facility will function as a crucial bridge between laboratory research and industrial-scale production, operating on a "pay-and-use" model to deeply democratize access for biotech startups developing cell-based therapies like CAR-T. **Strategic Importance** This is highly relevant for UPSC GS Paper 3 (Science and Technology, Biotechnology, Indigenization of Technology). It showcases India's strategic policy backing to aggressively become a global biomanufacturing hub. Expanding the deep-tech startup ecosystem powerfully reflects the government's dual focus on robust economic growth and affordable healthcare solutions. **Future Outlook** The full operationalization of recombinant cells and GMP facilities will dramatically accelerate the translation of scientific research into commercial therapeutics. Driven by the BioE3 policy and robust scientific initiatives, India is on a definitive track to achieve a $300 billion biomanufacturing economy, cementing its global leadership in emerging medical technologies.